8-K: Aquestive Therapeutics Reaffirms Anaphylm NDA Filing Timeline Following FDA Approval of Non-Injection Epinephrine Device

Aquestive Therapeutics has commented on the recent FDA approval of a non-injection epinephrine device and reiterated its plan to file a New Drug Application (NDA) for its Anaphylm sublingual film in the first quarter of 2025.

Summary

• Aquestive Therapeutics has acknowledged the FDA's approval of a non-injection epinephrine device.
• The company is reiterating its plan to submit a New Drug Application (NDA) for Anaphylm sublingual film in the first quarter of 2025.
• Aquestive anticipates a full product launch of Anaphylm by the end of 2025 or the first quarter of 2026, pending FDA approval.
• Anaphylm is designed as a sublingual film for rapid delivery of epinephrine, offering a needle-free alternative for anaphylaxis treatment.
• The company is currently completing its oral allergy syndrome (OAS) challenge study, expected to conclude late in the third quarter or early fourth quarter of 2024.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential of Anaphylm and reaffirming the timeline for NDA submission. However, it also acknowledges significant risks and uncertainties, which temper the overall sentiment.

Positives

• The recent FDA approval of a non-injection epinephrine device validates the market need for alternative delivery methods.
• Anaphylm has the potential to be the first and only oral epinephrine product for anaphylaxis.
• The sublingual film format of Anaphylm is designed for ease of use and portability.
• The company is on track to submit its NDA in the first quarter of 2025.
• The company has received conditional approval for the tradename Anaphylm.

Negatives

• The company is still subject to the risk of not receiving FDA approval for Anaphylm.
• There are risks associated with the commercialization of a new product, including market acceptance and competition.
• The company faces risks related to its ability to secure sufficient capital and cash resources.
• There are risks related to the company's manufacturing capabilities to meet demand.
• The company is subject to risks related to intellectual property rights and infringement claims.

Risks

• There are risks associated with the development of Anaphylm, including potential delays or changes to the timing, cost, and success of clinical trials.
• The company faces the risk of delays in the regulatory approval process or failure to receive FDA approval.
• There is a risk that the company may not generate sufficient data for FDA approval.
• The FDA may require additional clinical studies for approval of Anaphylm.
• The company faces risks from competing products, including generics.
• There are risks related to the company's ability to develop a sales and marketing capability for Anaphylm.
• The company faces risks related to its ability to secure sufficient capital and cash resources.
• There are risks related to the company's manufacturing capabilities to meet demand.
• The company is subject to risks related to intellectual property rights and infringement claims.
• The company is subject to risks related to general economic, political, business, industry, regulatory, financial and market conditions.

Future Outlook

Aquestive anticipates submitting the NDA for Anaphylm in the first quarter of 2025 and launching the product by the end of 2025 or the first quarter of 2026, pending FDA approval. The company is focused on completing its remaining supportive study and preparing for commercialization.

Management Comments

• Daniel Barber, President & Chief Executive Officer of Aquestive, stated that they are excited to see the FDA's recent approval of an alternative non-injection-based device form of epinephrine.
• Sung Poblete, PhD, RN, CEO of FARE, expressed encouragement by the FDA approval of the first alternate treatment for anaphylaxis and looks forward to seeing additional life-saving epinephrine delivery methods.
• John Oppenheimer, MD, Director of Clinical Research at Pulmonary and Allergy Associates, is pleased to see the first non-needle form of epinephrine for the treatment of anaphylaxis get approved by the FDA and is excited to see further innovation coming for patients with anaphylaxis.

Industry Context

The announcement comes after the FDA's recent approval of a non-injection epinephrine device, highlighting a growing trend towards less invasive and more convenient treatment options for anaphylaxis. This development underscores the market's need for alternatives to traditional needle-based epinephrine delivery, which Aquestive aims to address with its Anaphylm sublingual film.

Comparison to Industry Standards

• The current standard of care for anaphylaxis treatment is primarily epinephrine auto-injectors, such as EpiPen and Auvi-Q, which are needle-based.
• Aquestive's Anaphylm aims to differentiate itself by offering a needle-free, sublingual film delivery method, which could improve patient compliance and reduce injection hesitancy.
• The recent FDA approval of a non-injection epinephrine device by a competitor validates the market demand for alternative delivery methods, but Aquestive's sublingual film offers a unique approach.
• Other companies are also exploring alternative epinephrine delivery methods, such as nasal sprays, but Aquestive's sublingual film is positioned as a potentially more convenient and patient-friendly option.

Stakeholder Impact

• Shareholders will be impacted by the progress of Anaphylm and the company's ability to secure FDA approval and commercialize the product.
• Patients with severe allergies, including anaphylaxis, stand to benefit from a new, needle-free treatment option.
• Employees will be involved in the development, regulatory approval, and commercialization of Anaphylm.
• The company's suppliers and partners will be impacted by the production and distribution of Anaphylm.

Next Steps

• Aquestive will complete the oral allergy syndrome (OAS) challenge study.
• The company will prepare and submit the New Drug Application (NDA) for Anaphylm to the FDA in the first quarter of 2025.
• Aquestive will continue to develop its sales and marketing capabilities for the potential launch of Anaphylm.
• The company will monitor the regulatory review process and prepare for a potential product launch at the end of 2025 or in the first quarter of 2026.

Key Dates

Keywords

Anaphylm, epinephrine, sublingual film, FDA approval, NDA filing, anaphylaxis, oral administration, non-injection, pharmaceutical, drug delivery